Browse the evidence

GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.

Consider GLP-1 RAs or SGLT-2 inhibitors if you need better blood sugar control, weight loss, or heart protection. These drugs have strong evidence for reducing heart attacks and strokes. Be aware of potential stomach issues, which often improve over time.

Sustained weight loss of 5-10% or greater through negative energy balance interventions (behavioral, pharmacological, or surgical) prevents, reduces, or resolves obesity-related complications such as type 2 diabetes, hypertension, and fatty liver disease.

To significantly lower your risk of type 2 diabetes and other obesity-related diseases, you need to achieve and maintain a weight loss of at least 5-10% of your body weight. This can be done through lifestyle changes, medications, or surgery. The key is that the weight loss must be sustained over the long term, not just short-term dieting.

Greater magnitude of weight loss (e.g., >10-15%) is required to achieve remission of type 2 diabetes, whereas moderate weight loss (5-10%) is sufficient for prevention or delay.

If you want to prevent type 2 diabetes, losing 5-10% of your body weight is a great start. However, if you already have type 2 diabetes and want to achieve remission, you likely need to lose more than 10-15% of your body weight and keep it off.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.

If you have obesity or are overweight without diabetes, a once-weekly dual-acting injection (tirzepatide) can lead to significant weight loss (up to 21% in trials) and often reverses prediabetes. This is more effective than older GLP-1 drugs. It requires lifestyle changes alongside the medication.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide) significantly reduce body weight and improve glucose metabolism in non-diabetic obese individuals and those with prediabetes, often leading to normoglycemia.

For non-diabetic individuals with obesity or prediabetes, weekly GLP-1 injections (semaglutide 2.4 mg) can lead to significant weight loss (approx. 15%) and high rates of returning to normal blood sugar levels. This is more effective than lifestyle changes alone.

Adherence to a Mediterranean dietary pattern significantly reduces the risk of major cardiovascular events, all-cause mortality, and coronary heart disease mortality in both primary and secondary prevention populations.

Adopt a Mediterranean-style eating pattern as your default. Fill your plate with vegetables, fruits, legumes, nuts, and whole grains. Use extra virgin olive oil as your primary fat source and eat fatty fish regularly. Limit red meat, sweets, and processed foods. This pattern is proven to significantly lower your risk of heart attack, stroke, and death.

Replacing saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA) or monounsaturated fatty acids (MUFA) results in the greatest reduction in LDL cholesterol and apoB, whereas replacing SFA with carbohydrates yields only modest apoB lowering.

To lower your LDL cholesterol, replace saturated fats (found in red meat, full-fat dairy, and tropical oils) with unsaturated fats. Prioritize polyunsaturated fats (found in fatty fish, walnuts, and vegetable oils) and monounsaturated fats (found in olive oil and avocados). Avoid replacing these fats with refined carbohydrates like white bread or sugar, as this is less effective for lowering cholesterol.

Adherence to a DASH dietary pattern significantly lowers systolic and diastolic blood pressure, with greater effects observed in hypertensive individuals, and this effect is amplified by low sodium intake.

Follow the DASH diet: eat plenty of vegetables, fruits, whole grains, and low-fat dairy, while limiting red meat, saturated fat, and sugar. To maximize blood pressure benefits, also reduce your sodium intake. This combination is highly effective for lowering blood pressure, especially if you have hypertension.

Intensive lifestyle intervention (ILI) targeting weight loss and increased physical activity significantly improves glycemic control, promotes diabetes remission, and reduces microvascular complications (nephropathy and neuropathy) in adults with overweight/obesity and type 2 diabetes.

For adults with type 2 diabetes and obesity, committing to a structured lifestyle program that combines moderate calorie restriction (1200-1800 kcal) with regular moderate physical activity (175 mins/week) can significantly improve blood sugar control, reduce the risk of kidney and nerve damage, and even allow some to reverse their diabetes diagnosis, especially if started early in the disease course.

Discontinuation of GLP-1 therapy leads to significant weight regain (up to two-thirds of lost weight within 1 year), highlighting the necessity of long-term lifestyle interventions and potentially long-term medication use.

Understand that GLP-1 therapy is likely a long-term treatment for obesity. If you stop the medication, you will likely regain a significant portion of your lost weight. Work with your provider to determine if you should stay on the medication long-term or transition to a maintenance strategy that includes intensive lifestyle support.

Increasing physical activity reduces the incidence of type 2 diabetes in high-risk adults, with the magnitude of benefit being significantly greater for individuals who are less active at baseline.

To lower your risk of type 2 diabetes, aim for 150 minutes of moderate-intensity physical activity per week. This does not need to be continuous; it can be broken into smaller chunks, such as 17 minutes of brisk walking daily. This benefit exists independently of weight loss, meaning you gain protection even if your weight stays the same. If you are currently inactive, starting to move will yield the greatest reduction in your diabetes risk.

Discontinuation of anti-obesity medications (AOMs) after weight loss leads to significant weight regain (approx. two-thirds of lost weight) and reversal of cardiometabolic improvements, necessitating long-term treatment.

Obesity is a chronic condition. If you stop taking your medication after losing weight, you will likely regain most of that weight (about two-thirds) and lose the health benefits. Treatment should be viewed as long-term management, similar to blood pressure medication, rather than a short-term fix.

SGLT2 inhibitors are preferred over GLP1RAs for adults with type 2 diabetes and heart failure to reduce major adverse cardiovascular events and worsening heart failure, while GLP1RAs are preferred for chronic kidney disease if SGLT2is are not tolerated.

If you have type 2 diabetes and heart failure, ask about SGLT2 inhibitors (like empagliflozin or dapagliflozin), as they are proven to help your heart. If you have kidney disease, SGLT2 inhibitors are also preferred, but if you can't take them, GLP-1 agonists (like dulaglutide) are a good alternative for protecting your kidneys. Your doctor will choose based on your specific organ risks.

Creatine supplementation (3-5 g/day maintenance or 20 g/day loading) is safe and effective for increasing lean body mass and high-intensity exercise performance in physique athletes.

Take 3-5 grams of creatine monohydrate every day. You can take it anytime. If you want to saturate your muscles faster, take 20g/day for a week, then switch to 5g/day. It is safe and one of the most effective supplements for strength and muscle mass.

Metformin produces moderate weight loss (3-5% reduction) in adults with T2DM or obesity, primarily by lowering hunger and reducing calorie intake, and can prevent weight gain associated with antipsychotic medications.

Metformin is a cornerstone treatment for Type 2 Diabetes that also offers moderate weight loss benefits (typically 3-5% body weight reduction). It works by reducing appetite and calorie intake. It is particularly useful for patients who need to counteract weight gain caused by other medications, such as antipsychotics. While gastrointestinal side effects are common, they often subside, and the long-term weight and metabolic benefits are substantial.

Metabolic surgery (bariatric surgery) provides superior long-term glycemic control, higher T2D remission rates, and greater weight loss compared to intensive lifestyle and medical management alone in patients with Type 2 Diabetes and obesity.

If you have Type 2 Diabetes and obesity, standard diet and medication often fail to provide long-term remission. Metabolic surgery is a highly effective, standard-of-care option that offers significantly better weight loss and diabetes control than lifestyle changes alone, with safety profiles comparable to common surgeries.

Lisdexamfetamine dimesylate is the only FDA-approved medication for Binge Eating Disorder and significantly reduces binge eating days and increases binge cessation rates compared to placebo.

Lisdexamfetamine is the only FDA-approved medication for Binge Eating Disorder. Clinical trials show it significantly reduces binge eating days and increases the likelihood of stopping binges compared to a placebo. However, because it is a stimulant, it requires caution in patients with T2DM who may also have hypertension or cardiovascular issues. Discuss the risks and benefits with your doctor if you are considering medication.

GLP-1 receptor agonists improve glycemic control, promote significant weight loss, and reduce cardiovascular events in patients with type 2 diabetes.

If you have type 2 diabetes and heart risks, GLP-1 injections can help lower blood sugar, lose weight, and protect your heart.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to GLP-1 receptor agonists.

Tirzepatide is a newer injection that works on two hormones to lower blood sugar and lose more weight than older GLP-1 drugs.

Early weight loss (e.g., >= 5% at 3-4 months) is a strong predictor of sustained long-term weight loss across various obesity interventions, including pharmacotherapy and lifestyle modification.

Use the first 3-4 months of any obesity treatment as a critical checkpoint. If you haven't lost at least 5% of your body weight by then, it's a strong signal that the current plan may not work for you long-term. Discuss this with your provider to adjust the strategy rather than continuing a failing approach.

Bariatric surgery patients have extremely high rates of pre-existing micronutrient deficiencies, requiring comprehensive screening and aggressive post-operative supplementation.

If you are having bariatric surgery, get screened for nutrient deficiencies beforehand. Do not rely on standard multivitamins alone; you will likely need specific, higher-dose supplements tailored to your blood work to prevent long-term health issues.

Subcutaneous semaglutide (2.4 mg once weekly) produces clinically significant weight loss (mean -14.9% body weight) compared to placebo when combined with lifestyle interventions.

If you have obesity, adding weekly semaglutide (2.4 mg) to your existing diet and exercise plan can help you lose significantly more weight (around 15%) than diet and exercise alone. Start with the lowest dose and increase it slowly every few weeks to avoid stomach issues.

GLP-1 receptor agonists improve glycemic control and promote weight loss in type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion and reducing appetite, with efficacy superior to many existing therapies.

GLP-1 receptor agonists are highly effective treatments for Type 2 Diabetes and Obesity. They work by mimicking a natural hormone to increase insulin when blood sugar is high and reducing appetite. While they are usually given by injection (some are oral), they offer significant benefits in lowering blood sugar and losing weight, often more so than older diabetes medications. Common side effects like nausea are frequent but often improve over time. These drugs are not suitable for everyone, particularly those with a history of certain thyroid cancers or pancreatitis.

Multi-agonists targeting GLP-1R along with other receptors (GIPR, GCGR) demonstrate superior weight loss and glycemic control compared to single GLP-1R agonists.

Newer 'multi-agonist' diabetes and obesity drugs (like Tirzepatide) target multiple hormone receptors simultaneously. This approach often leads to greater weight loss and better blood sugar control than older single-target GLP-1 drugs. They are taken as weekly injections and are approved for both Type 2 Diabetes and Obesity.